Acdcrgdcfcg (disulfide bridge: 2-10 and 4-8)

RGD-4C (9.11 mg/kg; injection; single dose) inhibits the growth of B16F10 mouse melanoma in vivo^[2].
Modified RGD-4C fused with the N-terminus of plant-derived single-chain ribosome inactivating protein saporin (SAP) (called RGD-SAP), (diluted in sodium chloride, 0.9%; i.v.; 200 μL; every 5 days, for 3 times) exerts anti-tumor activity in a model of muscle invasive bladder cancer^[3].
RGD-SAP in combination with mitomycin C, a chemotherapeutic drug, increases the survival of mice bearing orthotopic bladder cancer with no evidence of systemic toxicity^[3].